TRANSGENE: Looking ahead of clinical development updates in H2 2022 | CORPORATE | EUR3.5
TRANSGENE - CORPORATE | EUR3.5Looking ahead of clinical development updates in H2 2022
Interim results from the phase 2 study of TG4001 in Q4 2022 should inform on best trial design
Additional data for TG4050 in H2 2022 could help to define clinical path forward
Other assets are progressing as planned, TG6002 poster at ESMO this week
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.